Dec. 8 Quick Takes: ADC play Dantari debuts with $47M led by Westlake 

Dantari Inc. launched on Thursday with $47 million raised in a series A round led by Westlake Village BioPartners. Other investors included Corner Ventures, Alexandria Venture Investments and Caltech. The company’s T-HDC platform allows for high capacity drug-antibody ratios for its antibody-drug conjugates (ADCs), with tuneable release of the chemotherapy. In parallel, the California-based biotech also named Richard Markus as president and CEO. 

Revolution Medicines Inc. (NASDAQ:RVMD) will move forward with RMC-4630 on its own after Sanofi (Euronext:SAN; NASDAQ:SNY) terminated the companies’ SHP2 inhibitor partnership. RMC-4630, part of a deal that gave Revolution $50 million up front and a chance at $500 million in milestones, is in Phase II testing with Lumakras sotorasib for non-small cell lung cancer patients with a KRAS G12C mutation, with top-line data due in 2H23. The termination announcement follows disappointing PD-1 combination data for KRAS G12C inhibitor adagrasib from Mirati Therapeutics Inc. (NASDAQ:MRTX), adding to growing doubts about the added benefits of KRAS inhibitor combination regimens. Revolution said it has cash runway through 2024...